Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Imatinib
100%
Nilotinib
100%
Mesylate
80%
Kinase
30%
Phosphotransferase
30%
Stem Cell
10%
Wild Type
10%
Point Mutation
10%
Gene Fusion
10%
Tyrosine Kinase Inhibitor
10%
Dasatinib
10%
Medicine and Dentistry
Chronic Myelogenous Leukemia
100%
Imatinib
100%
Nilotinib
100%
Disease
30%
Phosphotransferase
10%
Stem Cell
10%
Tyrosine-Kinase Inhibitor
10%
Point Mutation
10%
Emergency Medical Technician
10%
Phosphotransferase Inhibitor
10%
Dasatinib
10%
Abelson Kinase
10%
Gene Fusion
10%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Myeloid Leukemia
100%
Imatinib
100%
Nilotinib
100%
Disease
30%
Phosphotransferase
10%
Protein Tyrosine Kinase Inhibitor
10%
Phosphotransferase Inhibitor
10%
Dasatinib
10%
Abelson Kinase
10%
Keyphrases
Balanced-to-single-ended
14%
Fusion Oncogene
14%
Second-generation Tyrosine Kinase Inhibitors
14%
Imatinib Failure
14%